methotrexate + dexamethasone + polatuzumab vedotin + cyclophosphamide + doxorubicin + rituximab

MAD CPR 1 + MAD CPR 2 is an experimental chemo-immunotherapy regimen developed by New York Medical College for the treatment of children, adolescents, and young adults with mature B-cell non-Hodgkin lymphoma (MB-NHL). This regimen is a key component of the Phase 2 RADICAL clinical trial (NCT05439239), which investigates the safety and efficacy of adding targeted immunotherapies like polatuzumab vedotin and rituximab to a reduced-toxicity chemotherapy backbone. The 'MAD CPR' acronym represents its constituents: methotrexate, adriamycin (doxorubicin), dexamethasone, cyclophosphamide, polatuzumab vedotin, and rituximab. By incorporating polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, and rituximab, an anti-CD20 monoclonal antibody, the protocol aims to maintain high rates of disease control while significantly reducing exposure to anthracyclines and diagnostic radiation, thereby minimizing long-term toxicities in young patients.

Other names

MAD CPR